Two home-grown liquid chromatography with tandem mass spectrometry (LC-MS) systems, the ACQUITY UPLC I-Class PLUS / Xevo TQ-Loong System and the ACQUITY UPLC I-Class PLUS / Xevo TQ-S cronos System, have obtained marketing approvals from the National Medical Products Administration (NMPA). These products, developed jointly by US firm Waters Corporation (NYSE: WAT) and China’s Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), are used in clinical settings for qualitative or quantitative detection of endogenous (vitamins, amino acids, hormones, organic acids) or exogenous (therapeutic drugs) analytes in human biological samples, including whole blood, plasma, serum, and urine.
Product Highlights
The ACQUITY UPLC I-Class PLUS / Xevo TQ-Loong System is designed to meet the demanding requirements of UPLC-MS / MS quantitative analysis. Its excellent performance allows for the accurate quantification of trace analytes in complex clinical matrices, providing robust data support for clinical research. Meanwhile, the ACQUITY UPLC I-Class PLUS / Evo TQ-S cronos System offers stable performance and excellent cost-effectiveness, making it suitable for routine quantitative analysis in clinical laboratories.-Fineline Info & Tech
Leave a Reply